Bullish: Analysts Just Made A Meaningful Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts

Celebrations may be in order for CorMedix Inc. (NASDAQ:CRMD) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The analysts greatly increased their revenue estimates, suggesting a stark improvement in business fundamentals. Investors have been pretty optimistic on CorMedix too, with the stock up 10% to US$14.96 over the past week. We'll be curious to see if these new estimates convince the market to lift the stock price higher still.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Following the upgrade, the current consensus from CorMedix's six analysts is for revenues of US$165m in 2025 which - if met - would reflect a substantial 100% increase on its sales over the past 12 months. Per-share earnings are expected to jump 299% to US$1.01. Previously, the analysts had been modelling revenues of US$138m and earnings per share (EPS) of US$0.80 in 2025. So we can see there's been a pretty clear increase in analyst sentiment in recent times, with both revenues and earnings per share receiving a decent lift in the latest estimates.

See our latest analysis for CorMedix

It will come as no surprise to learn that the analysts have increased their price target for CorMedix 12% to US$18.83 on the back of these upgrades.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the CorMedix's past performance and to peers in the same industry. The analysts are definitely expecting CorMedix's growth to accelerate, with the forecast 152% annualised growth to the end of 2025 ranking favourably alongside historical growth of 101% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 8.5% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that CorMedix is expected to grow much faster than its industry.

The Bottom Line

The biggest takeaway for us from these new estimates is that analysts upgraded their earnings per share estimates, with improved earnings power expected for this year. Fortunately, analysts also upgraded their revenue estimates, and our data indicates sales are expected to perform better than the wider market. Given that the consensus looks almost universally bullish, with a substantial increase to forecasts and a higher price target, CorMedix could be worth investigating further.

Still, the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple CorMedix analysts - going out to 2027, and you can see them free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.